Valeo’s
Canadian Roots
Rooted in specialty pharma, Valeo is growing Canadian healthcare by licensing and acquiring Canadian rights to commercial stage, innovative, and proprietary drugs.
Founded in 2003, Valeo Pharma originally focused on dermatology and Hospital specialty, until 2014 when it sold its entire product portfolio to Valeant.
Management and a growing base of employees (125+) is now refocused on large new therapeutic areas and commercializing drugs in Canada.
Publicly traded since
February 2019
Listed on the TSX in
March 2022
Publicly traded since
February 2019
Listed on the TSX in
March 2022
Areas of Focus
Valeo’s company growth is coming by way of these therapeutic areas.
Within these areas, we now have 12 commercialized products contributing to 100% growth to our anticipated 2023 revenues.
3
Business Units
12
Commercialized Products
This focused growth plan is already resulting in pivotal growth in 2023:
100%
Growth Estimated
Valeo’s Fully Integrated
Capabilities
Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization
